Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 3693096, 10 pages
http://dx.doi.org/10.1155/2016/3693096
Research Article

Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer

1Department of Functional Genomics, Institute of Molecular Biology and Genetics of the National Academy of Science of Ukraine, Kyiv, Ukraine
2Department of Molecular Oncogenetics, Institute of Molecular Biology and Genetics of the National Academy of Science of Ukraine, Kyiv, Ukraine
3Institute of Urology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Received 10 June 2016; Revised 19 August 2016; Accepted 22 August 2016

Academic Editor: Olav Lapaire

Copyright © 2016 Inessa Skrypkina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The critical point for successful treatment of cancer is diagnosis at early stages of tumor development. Cancer cell-specific methylated DNA has been found in the blood of cancer patients, indicating that cell-free DNA (cfDNA) circulating in the blood is a convenient tumor-associated DNA marker. Therefore methylated cfDNA can be used as a minimally invasive diagnostic marker. We analysed the concentration of plasma cfDNA and methylation of six tumor suppressor genes in samples of 27 patients with renal cancer and 15 healthy donors as controls. The cfDNA concentrations in samples from cancer patients and healthy donors was measured using two different methods, the SYBR Green I fluorescence test and quantitative real-time PCR. Both methods revealed a statistically significant increase of cfDNA concentrations in cancer patients. Hypermethylation on cfDNA was detected for the LRRC3B (74.1%), APC (51.9%), FHIT (55.6%), and RASSF1 (62.9%) genes in patients with renal cancer. Promoter methylation of VHL and ITGA9 genes was not found on cfDNA. Our results confirmed that the cfDNA level and methylation of CpG islands of RASSF1A, FHIT, and APC genes in blood plasma can be used as noninvasive diagnostic markers of cancer.